Agomab Therapeutics is focused on developing innovative therapies that target fibrotic diseases, which are characterized by excessive tissue scarring and can lead to organ failure. The company leverages its expertise in growth factor biology to create a pipeline of small molecule and antibody drug candidates aimed at modulating growth factor pathways. Their lead candidate, AGMB-129, is an oral small molecule inhibitor of ALK5 (TGFβ1R) specifically designed for gastrointestinal applications, currently undergoing a Phase 2a clinical trial for fibrostenosing Crohn’s disease. Additionally, AGMB-447, an inhaled small molecule ALK5 inhibitor, is in Phase 1 trials for idiopathic pulmonary fibrosis, while AGMB-101, a full MET receptor agonist, is in the final stages of IND-enabling studies.

The company is committed to addressing the underlying fibrotic processes that contribute to various challenging diseases through its diverse pipeline. Agomab's approach includes the development of both small molecules and antibodies that target well-validated mechanisms to promote tissue repair and restore organ function. Their ongoing research and clinical trials reflect a dedication to advancing disease-modifying treatments, with plans to expand their pipeline further to meet the needs of patients suffering from fibrotic conditions.

Belgium

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

Agomab Therapeutics

Company Details